TY - JOUR
T1 - Advancing the prevention and treatment of HIV in children
T2 - priorities for research and development
AU - PADO-HIV 5 participants
AU - Penazzato, Martina
AU - Townsend, Claire L.
AU - Hafiz, Asma
AU - Archary, Moherndran
AU - Bekker, Adrie
AU - Capparelli, Edmund V.
AU - Colbers, Angela
AU - Cressey, Tim R.
AU - Cressey, Tim R.
AU - Frigati, Lisa
AU - Mukui, Irene
AU - Rakhmanina, Natella
AU - Rakhmanina, Natella
AU - Rakhmanina, Natella
AU - Ruel, Theodore D.
AU - Sam-Agudu, Nadia A.
AU - Sam-Agudu, Nadia A.
AU - Sugandhi, Nandita
AU - Abrams, Elaine J.
AU - Abrams, Elaine J.
AU - Rojo, Pablo
AU - Vicari, Marissa
AU - Watkins, Melynda
AU - Abrams, Elaine
AU - Archary, Moherndran
AU - Bekker, Adrie
AU - Capparelli, Edmund
AU - Colbers, Angela
AU - Cressey, Tim
AU - Frigati, Lisa
AU - Hafiz, Asma
AU - Mukui, Irene
AU - Penazzato, Martina
AU - Rakhmanina, Natella
AU - Rojo, Pablo
AU - Ruel, Theodore
AU - Sam-Agudu, Nadia
AU - Sugandhi, Nandita
AU - Townsend, Claire
AU - Vicari, Marissa
AU - Watkins, Melynda
N1 - Publisher Copyright:
© 2022 World Health Organization. Published by Elsevier Ltd. All rights reserved
PY - 2022/9
Y1 - 2022/9
N2 - Safe and effective paediatric formulations of the most promising antiretroviral drugs are crucial to advance the treatment and prevention of HIV in neonates, infants, children, and adolescents. The WHO Paediatric Drug Optimization for HIV (PADO-HIV) group brings together stakeholders and experts every 2–3 years to identify priority products and define research gaps in the development of new HIV drugs and formulations for children in low-income and middle-income countries. PADO-HIV 5 met from Sept 27 to Oct 15, 2021. The group evaluated HIV agents from known and novel drug classes, oral and parenteral long-acting formulations, and developments in broadly neutralising antibodies, and included focused sessions on neonates and new delivery technologies. A list of medium-term and long-term priorities was generated, and research questions were defined. This forward-looking analysis is intended to provide guidance to funders, drug developers, and researchers, and to accelerate access for children to the best HIV drugs and formulations.
AB - Safe and effective paediatric formulations of the most promising antiretroviral drugs are crucial to advance the treatment and prevention of HIV in neonates, infants, children, and adolescents. The WHO Paediatric Drug Optimization for HIV (PADO-HIV) group brings together stakeholders and experts every 2–3 years to identify priority products and define research gaps in the development of new HIV drugs and formulations for children in low-income and middle-income countries. PADO-HIV 5 met from Sept 27 to Oct 15, 2021. The group evaluated HIV agents from known and novel drug classes, oral and parenteral long-acting formulations, and developments in broadly neutralising antibodies, and included focused sessions on neonates and new delivery technologies. A list of medium-term and long-term priorities was generated, and research questions were defined. This forward-looking analysis is intended to provide guidance to funders, drug developers, and researchers, and to accelerate access for children to the best HIV drugs and formulations.
UR - http://www.scopus.com/inward/record.url?scp=85137103401&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85137103401&partnerID=8YFLogxK
U2 - 10.1016/S2352-3018(22)00101-1
DO - 10.1016/S2352-3018(22)00101-1
M3 - Review article
C2 - 35863362
AN - SCOPUS:85137103401
SN - 2352-3018
VL - 9
SP - e658-e666
JO - The Lancet HIV
JF - The Lancet HIV
IS - 9
ER -
